P.et al (2016)
Guillemin, PLoS One 7 (2012) e42357
To view or add a comment, sign in 10,835 followers More from this author Dr Labo LIMS Custom Plan - Multiple Location, Multiple User Access, Unlimited Reports, Machine Integration & More Premium Features Medikamart 7mo Dr Labo Enterprise Plan Multiple User Access, Patient Referral Medikamart 7mo Dr Labo Standard Plan Single User, Unlimited Reports Medikamart 7mo
Investigations of the Connectivity Map and high-throughput transcriptional profiling suggested that GHK (and by extension GHK-Cu) may up- or down-regulate thousands of genes, many of which are associated with tissue regeneration, extracellular matrix biology, inflammation, and oxidative stress response
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
While no officially approved human dosing exists, community experience and extrapolation from animal research provide useful guidance
